ICPE 2022: It takes a village to advance Pharmacoepidemilogy science

By Katica Boric on behalf of Teamit Institute team.

August 24th, 2022, marked the long-awaited return to face-to-face meetings of the  International Society for Pharmacoepidemiology (ISPE). After a couple of years of remote interactions, the annual International Conference of Pharmacoepidemiology (ICPE) was hosted in Copenhagen, Denmark and our team had the honour of attending, and contributing with two poster presentations.

The excitement was tangible, and the attendance was record-breaking for a European meeting. More than 1500 attendees were very eager to interact, reconnect, or meet for the first time in “real life”, and of course to learn about the latest in pharmacoepidemiology science. The 4-day conference that gathered the industry, academia, health authorities, and non- and for-profit organisations had a program that focused on sharing the experience of how the pharmacoepidemiology community joined forces to tackle an unprecedented emergency scenario in the field during the COVID-19 pandemic.

Most keynote talks, workshops, symposia, and poster presentations highlighted the advancements achieved and reflected on the problems faced during the pandemic, and lessons learned. The main and common fundamental points among those stories of success were effective collaboration, management, coordination, and communication; all of which highlight the significant role scientific study managers play in the advancement of pharmacoepidemiologic and regulatory science research. Along the same line, our team presented the poster “Conducting observational multi-country studies for regulatory decision making during COVID-19 Pandemic: the strategic role of the scientific study manager”. Our poster focused on identifying management challenges in the design and execution of post-authorisation safety studies (PASS) during the COVID-19 pandemic and provided an overview of optimal methodological procedures for agile management that are also compliant with regulatory requirements. You can read the full poster here.

Furthermore, Teamit Institute was also represented by our colleague Natasha Yefimenko, a co-author in the ”VAC4EU Active Safety Surveillance Study of The BNT162b2 COVID-19 Vaccine in Five European Countries: Study Design and First Results” poster, along Daniel Weibel and collaborators.


Teamit Institute team at ICPE 2022: Fabio Riefolo, Dana Danielescu, Gianmarco Di Mauro, Natasha Yefimenko, Katica Boric and Eva Molero

We are very proud to have taken part in ICPE 2022, a conference that not only showcases frontier research on pharmacoepidemiology, but also fosters discussion on regulatory decision-making.  This year, sustainability was one of the main topics of debate: how all created networks, common tools, protocols, methods, and platforms can be sustainable over time? The main home-take message is that, to keep up with this accelerated path of development and innovation, it takes a village! In other words, broad collaboration is needed to advance global health, a concept embedded into Teamit Institute’s DNA.

We strongly believe that this village also needs the expertise of a scientific study manager to be able to thrive and be sustainable.  Accordingly, for the past 18 months, Teamit Institute has been working to provide expert support to the generation of real-world evidence for the evaluation and supervision of medicines and the use of innovative research methodologies. Moreover, Teamit Institute is committed to the creation and development of strong partnerships in the area of pharmacoepidemiology for the advancement of global health, such as VAC4EU and the EU-ADR Alliance.

You can download our brochure for more information about us and what we do.

Looking forward to ICPE 2023!